SARS-CoV-2 and vaccine uptake among First Nations, Inuit and Métis peoples in urban areas

vaccine
Credit: Unsplash/CC0 Public Domain

Despite prioritizing Indigenous populations for SARS-CoV-2 vaccinations, vaccine uptake was low among First Nations, Inuit and Métis Peoples in Toronto and London, Ontario, according to new research published in CMAJ (Canadian Medical Association Journal).

As more than half of Indigenous Peoples in Canada live in urban areas, it is critical to understand the impact of the COVID-19 pandemic, which exacerbated existing health inequities, on these populations.

“Dense and multigenerational social networks; barriers in access to culturally safe health care; and a disproportionate burden of poverty, chronic disease and inadequate housing create conditions for the spread of SARS-CoV-2 among First Nations, Inuit and Métis living in urban areas in Canada,” writes Dr. Janet Smylie, St. Michael’s Hospital, a site of Unity Health Toronto, and the Dalla Lana School of Public Health, University of Toronto, with coauthors.

To fill gaps in understanding, a team of Indigenous and allied researchers co-led by Dr. Janet Smylie, Cheryllee Bourgeois, Seventh Generation Midwives Toronto and Dr. Michael Rotondi, York University, in partnership with Indigenous agencies, aimed to generate data on rates of SARS-CoV-2 testing and vaccination, and incidence of infection among First Nations, Inuit and Métis living in Toronto and London, Ontario. They included data on population-representative samples of 723 and 364 people over age 15 in each city respectively. The rate for 2-dose vaccination among First Nations, Inuit and Métis in Toronto was 58% compared with 79% for the overall population. In London, 2-dose completion was 61% for Indigenous populations compared with 82% for the overall population.

As well, vaccination rates among First Nations, Inuit and Métis in Toronto and London lagged behind overall vaccination rates among First Nations living on and off reserve in Ontario and national rates for First Nations on reserve. The authors suggest these differences in vaccination rates could be because of delayed access to vaccines in cities as well as Indigenous peoples’ mistrust of vaccines and of the urban hospitals leading Ontario’s vaccination campaigns.

“Multigenerational colonial policies that aimed to assimilate First Nations, Inuit and Métis Peoples and appropriate land and resources have led to inequities across most major health outcome for First Nations, Inuit and Métis living in urban, rural and remote geographies compared with non-Indigenous people in Canada, as well as striking gaps in access to equitable and culturally safe health care,” write the authors.

With new variants arising, these lower vaccination rates are concerning.

“There is a time-sensitive need to amplify Indigenous-focused COVID-19 response measures to prevent widespread SARS-CoV-2 infection among those who are not vaccinated with a subsequent surge in hospital admissions and mortality caused by COVID-19 among First Nations, Inuit and Métis,” they write.

Testing rates for SARS-CoV-2 among First Nations, Inuit and Métis were higher in Toronto (54%) than local and provincial rates. Community partnerships and outreach and culturally safe access to testing and vaccination can help lessen the burden of COVID-19 on these populations.

“Localized by-community-for-community approaches have successfully engaged First Nations, Inuit and Métis living in cities in the COVID-19 response and could be used to further improve access to trusted COVID-19 information sources and culturally safe vaccination opportunities,” they suggest.



More information:
Uncovering SARS-CoV-2 vaccine uptake and COVID-19 impacts among First Nations, Inuit and Métis Peoples living in Toronto and London, Ontario, Canadian Medical Association Journal (2022). DOI: 10.1503/cmaj.212147

Citation:
SARS-CoV-2 and vaccine uptake among First Nations, Inuit and Métis peoples in urban areas (2022, August 2)
retrieved 10 August 2022
from https://medicalxpress.com/news/2022-08-sars-cov-vaccine-uptake-nations-inuit.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
"李 기대 높아" "'정권교체' 대세"… 설 연휴 여론조사 민심 '초박빙' thumbnail

“李 기대 높아” “‘정권교체’ 대세”… 설 연휴 여론조사 민심 ‘초박빙’

대다수 조사서 李·尹 오차 내 접전與 “마음 못 정한 중도층 상당수행정 경험 있는 李에 기대 높아”野 “현 정권 향한 민심의 분노 커정권교체 바라는 목소리 높아” 더불어민주당 이재명 대선 후보(왼쪽), 국민의힘 윤석열 대선 후보. 연합뉴스 더불어민주당 이재명 대선 후보와 국민의힘 윤석열 대선 후보는 이번 설 연휴 기간 지지율 조사에서 오차범위 내 접전 양상을 보였다. 대선을 한…
Read More
New position at Ichilov: Director of LGBT medicine thumbnail

New position at Ichilov: Director of LGBT medicine

בית החולים איכילוב הודיע היום על תפקיד חדש במערכת: מנהל תחום רפואת להט"ב. את התפקיד ימלא ד"ר רועי צוקר, מומחה ברפואה פנימית ומחלות זיהומיות, שנשלח בעזרת "איכילוב" להתמחות הראשונה בעולם בתחום זה בבית החולים הר סיני בניו יורק. מהנלת בית החוים נמסר כי "נושא רפואת הלהט"ב הולך ומתפתח עם השנים במדינות מערביות אשר מבינות כי…
Read More
Publisher’s Platform: I have some questions about the infant formula outbreak — Why was there a two-year gap in FDA inspections at plant? thumbnail

Publisher’s Platform: I have some questions about the infant formula outbreak — Why was there a two-year gap in FDA inspections at plant?

First some basic facts: One ill with Salmonella, Three ill with Cronobacter sakazakii with one death in Minnesota, Ohio and Texas Findings to date include several positive Cronobacter results from environmental samples taken by FDA at Abbott in Sturgis, Michigan facility. A review of the Abbott ’s internal records also indicate environmental contamination with Cronobacter…
Read More
Growing Controversy Over 'Skinny' Labeling for Generic Drugs thumbnail

Growing Controversy Over ‘Skinny’ Labeling for Generic Drugs

The vast majority of patients who initiated imatinib therapy for gastrointestinal stromal tumors (GISTs) received a generic drug that did not have FDA approval for that indication, a large retrospective review showed. Almost half of the 2,000 patients in the review of imatinib initiators had chronic myeloid leukemia (CML), while about a third had GIST.…
Read More
Index Of News
Total
0
Share